K
Kylix Bio focuses on translational development to accelerate gene therapy solutions for rare diseases. The company advances an AAV gene therapy pipeline through rigorous scientific research and development. They aim to provide life-altering treatments to patients without requiring families to fundraise.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Kylix Bio focuses on addressing the challenges within rare disease development, specifically bridging the "Valley of Death" in this sector. The company works to advance therapeutic candidates through critical stages of preclinical and early clinical development. This effort aims to accelerate the path for novel treatments reaching patients with unmet needs in rare diseases.